Pneumothorax due to mycetoma is extremely rare and has been described only in patients undergoing intensive cytotoxic therapy for hematologic malignancies. A non-immunocompromised subject presenting with pneumothorax due to rupture of the mycetoma into the pleural cavity is being described here.
INTRODUCTION
Aspergillus infection in the lung is known to lead to obstructive bronchopulmonary aspergillosis, mucoid impaction of the airways, tracheobronchitis, ulcerative bronchitis, pseudomembranous tracheobronchitis, invasive aspergillosis, or aspergilloma. Old tuberculosis cavities remain the most frequent underlying sites, and were recorded in up to 70% of cases. [1] Out of various complications, massive haemoptysis is the most fearsome that necessitates an early surgical intervention. Pneumothorax is not identified as a common complication of ruptured mycetoma.
CASE REPORT
A 22-year-male, farmer by occupation, presented with the acute onset of breathlessness, chest pain over the right side of the chest, moderate to high grade fever, and dry cough-all for duration of 2 days. There was no history of diabetes, hypertension, or any other significant disease/ disorder. The patient had a past history of smear positive pulmonary tuberculosis 3 years back for which he was advised antituberculosis drugs (ATT); he defaulted when advised first time but completed second regimen of ATT (2S 3 H 3 R 3 Z 3 E 3 / 1H 3 R 3 Z 3 E 3 /5H 3 R 3 E 3 ), subsequently. After completion of treatment, he was declared cured of pulmonary tuberculosis though he continued to have a thin walled cavity. 
DISCUSSION
Aspergillus is a ubiquitous fungus found in soil, water, and decaying matter. It is known to cause a wide variety of respiratory conditions including allergic bronchopulmonary aspergillosis, parenchymal invasion, and mycetoma. Mycetomas have a predisposition to occur in preexisting pulmonary cavities. Aspergillus fumigatus is the most common saprophytic species of aspergillus leading to aspergilloma. [2] In non-immunocompromised population, mycetomas have been reported to occur in 10% to 15% of patients with cavitating lung diseases. [3] In regions where the incidence of tuberculosis is on decline, mycetomas are increasingly identified in advanced sarcoidosis, pneumonoconioses, bullous emphysema, bronchiectasis, lung abscess, neoplasms, and pulmonary infarcts. [4] Invasive aspergillus parenchymal infection is reported to affect 5 to 8% of solid-organ transplant recipients with a 50 -100% mortality. [5] In HIV seropositve patients, P carinii pneumonia is a major risk factor for pulmonary aspergilloma. [6] The patients with mycetoma are often asymptomatic. Amongst symptomatic, the most common symptoms include cough and haemoptysis. The course of disease is highly variable, and patients are usually kept under observation without therapy unless they develop haemoptysis. [7] Massive haemoptysis necessitates surgical intervention with resection of the affected lung, or arterial embolization in the patient who is not suitable for surgery. The antifungal drugs -itraconazole, voriconazole, or amphotericin B -are used if complete surgical removal is not possible, or if the aspergillus infection has expanded beyond the aspergilloma. [8] A combination of antifungal and antiretroviral therapy has been shown to improve the clinical outcome in HIV-infected patients with pulmonary mycetoma. [9] Pneumothorax due to rupture of a mycetoma into the pleural space in patients who are not otherwise immunocompromised, to best of our knowledge, has not been reported in recent medical literature.
Pneumothorax has been described in patients with pulmonary mycetoma undergoing intensive cytotoxic therapy for hematologic malignancies. [10] In present case, the patient was not 
